UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Neuroendocrinology, 2017-09, Vol.105 (3), p.295-309

2017

Volltextzugriff (PDF)

Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27

Zeitschrift fur Gastroenterologie, 2018-06, Vol.56 (6), p.583

2018

Volltextzugriff (PDF)

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT

European journal of nuclear medicine and molecular imaging, 2010-01, Vol.37 (1), p.67-77

2010

Volltextzugriff (PDF)

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

The Lancet (British edition), 2011-12, Vol.378 (9808), p.2005-2012

2011

Volltextzugriff (PDF)

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study

The oncologist (Dayton, Ohio), 2024-05, Vol.29 (5), p.e643-e654

2024

Volltextzugriff (PDF)

Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial

The journal of clinical endocrinology and metabolism, 2015-04, Vol.100 (4), p.1511-1519

2015

Volltextzugriff (PDF)

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

The New England journal of medicine, 2011-02, Vol.364 (6), p.501-513

2011

Volltextzugriff (PDF)

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Journal of clinical oncology, 2017-01, Vol.35 (1), p.14-23

2017

Volltextzugriff (PDF)

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Endocrine-related cancer, 2018-03, Vol.25 (3), p.309-322

2018

Volltextzugriff (PDF)

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

European journal of cancer (1990), 2016-05, Vol.58, p.41-51

2016

Volltextzugriff (PDF)

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Neuroendocrinology, 2017-01, Vol.105 (3), p.245-254

2017

Volltextzugriff (PDF)

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

Clinical therapeutics, 2018-12, Vol.40 (12), p.2006-2020.e2

2018

Volltextzugriff (PDF)

ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology

Journal of neuroendocrinology, 2022-03, Vol.34 (3), p.e13100-n/a

2022

Volltextzugriff (PDF)

Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours

Neuroendocrinology, 2022-05, Vol.112 (6), p.595-605

2022

Volltextzugriff (PDF)

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study

Cancer chemotherapy and pharmacology, 2019-02, Vol.83 (2), p.375-385

2019

Volltextzugriff (PDF)

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Clinical therapeutics, 2017-11, Vol.39 (11), p.2158-2168

2017

Volltextzugriff (PDF)

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Neuroendocrinology, 2022-03, Vol.112 (3), p.298-310

2022

Volltextzugriff (PDF)

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms

Neuroendocrinology, 2019-01, Vol.108 (1), p.26-36

2019

Volltextzugriff (PDF)

Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

BMC cancer, 2021-11, Vol.21 (1), p.1206-9, Article 1206

2021

Volltextzugriff (PDF)

Long‐Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome

The oncologist (Dayton, Ohio), 2019-08, Vol.24 (8), p.e662-e670

2019

Volltextzugriff (PDF)

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Clinical therapeutics, 2018-06, Vol.40 (6), p.952-962.e2

2018

Volltextzugriff (PDF)

Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms

Anticancer research, 2018-07, Vol.38 (7), p.3863-3870

2018

Volltextzugriff (PDF)

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

Journal of gastrointestinal cancer, 2021-03, Vol.52 (1), p.212-221

2021

Volltextzugriff (PDF)

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

Neuroendocrinology, 2015-01, Vol.102 (1-2), p.18-25

2015

Volltextzugriff (PDF)

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial

Targeted oncology, 2016-12, Vol.11 (6), p.815-824

2016

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(52)
Mit Volltextzugriff
(57)

Publikationsform

Artikel
(59)
Buchkapitel
(9)

Sprache

Englisch
(54)
Deutsch
(15)
Japanisch
(6)

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(45)
Humans
(34)
Female
(19)
Male
(18)
Oncology
(18)
Neuroendocrine Tumors
(17)
Aged
(15)
Middle Aged
(15)
Endocrinology & Metabolism
(14)
Neurosciences
(14)
Neurosciences & Neurology
(14)
Adult
(13)
Neuroendocrine Tumors - Pathology
(11)
Aged, 80 And Over
(10)
Tumors
(10)
Biological And Medical Sciences
(9)
Diarrhea
(8)
Neuroendocrine Tumors - Drug Therapy
(8)
Carcinoid Syndrome
(7)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27

Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET/CT

Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study

Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study

Telotristat Etiprate for Carcinoid Syndrome: A Single-Arm, Multicenter Trial

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome

Telotristat ethyl in carcinoid syndrome: safety and efficacy in the TELECAST phase 3 trial

Effectiveness and side-effects of peptide receptor radionuclide therapy for neuroendocrine neoplasms in Germany: A multi-institutional registry study with prospective follow-up

ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pre- and Perioperative Therapy in Patients with Neuroendocrine Tumors

Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR

ENETS standardized (synoptic) reporting for neuroendocrine tumour pathology

Localization Defines Streptozotocin/5-FU Response in Primary Pancreatic Neuroendocrine Tumours

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study

Understanding the Patient Experience with Carcinoid Syndrome: Exit Interviews from a Randomized, Placebo-controlled Study of Telotristat Ethyl

Long-Term Treatment with Telotristat Ethyl in Patients with Carcinoid Syndrome Symptoms: Results from the TELEPATH Study

Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms

Ramucirumab in combination with dacarbazine in patients with progressive well-differentiated metastatic pancreatic neuroendocrine tumors (RamuNET): study protocol for a multicenter single-arm trial

Long‐Term Safety Experience with Telotristat Ethyl Across Five Clinical Studies in Patients with Carcinoid Syndrome

Changes in Weight Associated With Telotristat Ethyl in the Treatment of Carcinoid Syndrome

Immunohistochemical Study of Mitosis-regulatory Proteins in Gastroenteropancreatic Neuroendocrine Neoplasms

Time to Sustained Improvement in Bowel Movement Frequency with Telotristat Ethyl: Analyses of Phase III Studies in Carcinoid Syndrome

Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial

Patient-Reported Outcomes and Quality of Life with Sunitinib Versus Placebo for Pancreatic Neuroendocrine Tumors: Results From an International Phase III Trial

Suchergebnisse filtern